Skip to main content
Fig. 6 | Chinese Medicine

Fig. 6

From: Honokiol acts as an AMPK complex agonist therapeutic in non-alcoholic fatty liver disease and metabolic syndrome

Fig. 6

AMPK activation is required for honokiol-mediated beneficial effects in vitro. A Western blots of p-AMPKα, AMPKα, p-ACC, and ACC in primary hepatocytes challenged with PA for 18 h under the indicated conditions. n = 3 replicates B Representative images (left) of BODIPY staining and quantification (right) of lipid droplets in primary hepatocytes challenged with PO under the indicated conditions. n = 3 replicates. One-way ANOVA was used for statistical analysis. Scale bar 10 μm. C TG and TC of primary hepatocytes challenged with PO stimulation for 18 h under the indicated conditions. n = 6 mice per group. One-way ANOVA was used for statistical analysis. D Western blots of p-AMPKα, AMPKα, p-ACC, and ACC in WT or PRKAA1/2 (encoding AMPKα1/2) double-knockout (DKO) hepatocytes challenged with PA for 18 h under the indicated conditions. E Representative images (left) of BODIPY staining and quantification (right) of lipid droplets in WT or PRKAA1/2 DKO L02 hepatocytes challenged with PO for 12 h under the indicated conditions. n = 3 replicates. One-way ANOVA was used for statistical analysis. Scale bar 10 μm. F TG and TC of WT or PRKAA1/2 DKO hepatocytes challenged with PO stimulation for 18 h under the indicated conditions. G Dot plot representing pairwise GSVA comparisons of transcriptomic data from primary hepatocytes challenged with PA for 18 h under the indicated conditions

Back to article page